Streetbeat News

Earnings

AAPL

AMD

INTC

NVDA

TSM

Taiwan Semiconductor Manufacturing Co (TSMC) CEO C.C. Wei will become chairman, succeeding Mark Liu. Under Wei's leadership, TSMC's market value nearly tripled. The company has heavily invested in R&D and capital expenditure to stay ahead of competitors like Intel and Samsung. TSMC's stock is trading higher after a sector selloff due to the U.S. AI chip embargo on the Middle East. TSMC faces political uncertainties, and its expansion includes new sites in Japan, Germany, and the U.S. Nvidia and AMD are also mentioned in the context of competition and partnerships.

Portfolio Pulse from Anusuya Lahiri

June 03, 2024 | 1:13 pm

MASI

Over the past three months, six analysts have evaluated Masimo (NASDAQ:MASI), with opinions ranging from bullish to bearish. Recent ratings show a trend towards more positive outlooks, with an average 12-month price target of $155.0, up from $129.67. Analysts have raised their price targets, reflecting a more optimistic view despite Masimo's recent revenue and profitability challenges.

Portfolio Pulse from Benzinga Insights

June 03, 2024 | 1:00 pm

IONS

Ionis Pharmaceuticals (NASDAQ: IONS) has received mixed analyst ratings over the past three months, with 3 bullish and 3 somewhat bullish ratings. The average 12-month price target has decreased by 3.3% to $68.17. Analysts have maintained, raised, or lowered their ratings based on recent developments. Ionis faces revenue challenges with a decline of -8.45% over the past three months, and its financial metrics such as ROE, ROA, and debt-to-equity ratio indicate potential financial difficulties.

Portfolio Pulse from Benzinga Insights

June 03, 2024 | 1:00 pm

HIBB

Analysts have provided mixed ratings for Hibbett (NASDAQ:HIBB) over the past quarter, with a majority being indifferent. The average 12-month price target has increased to $81.9, up 8.64% from the previous target. Hibbett has shown strong financial performance with notable revenue growth, net margin, ROE, and ROA, and maintains a prudent debt management strategy.

Portfolio Pulse from Benzinga Insights

June 03, 2024 | 1:00 pm

AMD

BTCUSD

GME

MSFT

NVDA

The article covers various financial news, including Bitcoin surpassing $69K with potential to rise to $74,400, 'Roaring Kitty' disclosing a significant GameStop stake, and notable movements in meme stocks like GameStop and AMC. Additionally, it mentions Nvidia's stock surge, AMD's new AI chips, and Microsoft's investment in AI and cloud in Sweden.

Portfolio Pulse from Akanksha Bakshi

June 03, 2024 | 12:56 pm

NNDM

Nano Dimension reported a Q1 2024 GAAP EPS of $(0.15), down from $0.09 year-over-year, and sales of $13.36 million, down from $14.96 million year-over-year.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:56 pm

CARR

GCAD

HON

Honeywell International Inc. (HON) has raised its second-quarter and FY24 guidance following the acquisition of Carrier Global Corporation's (CARR) Global Access Solutions business for $4.95 billion. The acquisition is expected to be earnings accretive in the first full year. Honeywell projects increased sales, adjusted EPS, and segment margins for FY24 and Q2 FY24. Investors can gain exposure to Honeywell via ETFs like GCAD and PPA.

Portfolio Pulse from Lekha Gupta

June 03, 2024 | 12:53 pm

EVAX

Evaxion Biotech A/S (NASDAQ:EVAX) presented data from its ongoing Phase 2 trial of the AI-designed cancer vaccine EVX-01 at the ASCO Annual Meeting 2024. The data showed a specific and tumor-targeting immune response in melanoma patients, validating the precision of Evaxion's AI-Immunology™ platform.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:47 pm

INDP

Indaptus Therapeutics announced new data from its ongoing Phase 1 trial of Decoy20, showing rapid clearance, broad immune activation, and an encouraging safety profile. The data were presented at the ASCO Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:39 pm

CYCC

CYCCP

Cyclacel Pharmaceuticals presented new clinical, pharmacokinetic, and pharmacodynamic data on their novel CDK2/9 inhibitor, fadraciclib, at the 2024 ASCO Annual Meeting. The data supports ongoing studies in patients with solid tumors and lymphoma.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:38 pm